A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose - Takeuchi, Fumihiko; McGinnis, Ralph; Bourgeois, Stephane; Barnes, Chris; Eriksson, Niclas; Soranzo, Nicole; Whittaker, Pamela; Ranganath, Venkatesh; Kumanduri, Vasudev; McLaren, William; Holm, Lennart; Lindh, Jonatan; et al. (PLoS genetics, 2009)
Keywords: Anticoagulants; Aryl Hydrocarbon Hydroxylases - genetics; Clinical pharmacology; Cytochrome P-450; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System - genetics; Cytochrome P450 Family 4; Dosage and administration; Drug dosages; Farmakologisk forskning; Fysiologi och farmakologi; Genes; Genetic aspects; Genetics; Genetics and Genomics/Pharmacogenomics; Genetik; Genome-Wide Association Study; Genomes; Genotype & phenotype; Humans; Klinisk farmakologi; Mathematics/Statistics; MEDICIN; MEDICINE; Metabolism - genetics; Mixed Function Oxygenases - genetics; Patients; Pharmacogenetics; Pharmacogenetics - methods; Pharmacological research; Pharmacology/Personalized Medicine; Physiological aspects; Physiology and pharmacology; Polymorphism, Single Nucleotide; Single nucleotide polymorphisms; Stroke; Sweden; Vitamin K Epoxide Reductases; Warfarin; Warfarin - administration & dosage; Warfarin - metabolism; Australia; Sweden